Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches
Alvotech Ordinary Shares · Now $3.22
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS